|Over a week ago|
BioSig Technologies 4.67M share Spot Secondary priced at $0.75 » 09:3906/2406/24/22
Laidlaw is acting as sole…
Laidlaw is acting as sole book running manager for the offering.
BioSig Technologies announces common stock offering, no amount given » 16:2706/2306/23/22
BioSig Technologies announced that it intends to offer shares of its common stock in a "best efforts" underwritten public offering. Laidlaw & Company is acting as sole book-running manager for the offering. BioSig intends to use the net proceeds from the offering for the continuation of commercialization activities related to the PURE EP System, including additional support for organizational development, to fund working capital, and for general corporate purposes and other capital expenditures.
BioSig enters new evaluation agreement for PURE EP with Cleveland clinic » 08:0906/2206/22/22
BioSig Technologies announced it has entered an evaluation agreement for its PURE EP System with the Cleveland Clinic. The evaluation agreement marks the first since BioSig inducted a new commercialization team. Consistent with The Company's stated national rollout strategy, Cleveland Clinic will participate in a 60-day evaluation of BioSig's PURE EP System. The Company recently announced that is has restructured its clinical support and installation teams to streamline and accelerate the pathway from product evaluation to adoption. "We are excited to include Cleveland Clinic as an evaluation center for the Pure EP System. We look forward to working alongside their physicians to demonstrate the superior signal quality that can be achieved on even the most difficult arrhythmias," commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies.
|Over a month ago|
BioSig Technologies rolls out national commercial launch campaign » 09:1305/2605/26/22
BioSig Technologies announced the rollout of the Company's national commercial launch campaign. Under the leadership of its Chief Commercial Officer Gray Fleming, BioSig has implemented several important initiatives to accelerate the transition from its limited market release to a national launch of its PURE EP System. The Company currently has over 30 qualified leads ahead of its official commercial kick-off, expected to commence on July 1, 2022. The PURE EP is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP System. Commercial strategy highlights include: Business agreement with Summit Blue Capital to implement a leasing and finance program for the PURE EP System. The agreement aims to expedite the pathway to purchase and increase the of scope PURE EP adopters across the U.S. Streamlined product evaluations from 180-360 days to 60 days with a succinct clinical and economic value proposition that showcases the advantages of the technology and accelerates adoption. Strengthened management, commercial, clinical, and marketing teams under the leadership of Gray Fleming, Chief Commercial Officer, who spent 18 years with St. Jude Medical/Abbott. Restructured clinical support and installation teams in preparation for increased commercial activity. The Company's new commercial structure includes national account directors covering five regions in the United States to support product evaluations and the rapid transformation of qualified leads into sales. Implemented an effective CRM system and pipeline management system to support sales opportunities and streamline data and customer engagements. Company to implement new brand strategy and marketing programs to reflect business growth and evolution. These efforts include an updated website and new visual content and branding.
BioSig: PURE EP system has completed over 2,200 patient cases » 08:3605/1105/11/22
To date, company's…
To date, company's FDA 510(k) cleared PURE EP system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, BioSig said in a statement. "We have made great strides on multiple fronts and felt it was an important time to communicate to our shareholders the strength of our business and the initiatives we are executing that have served as the foundation for our growth trajectory," said Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. "We strongly believe in the value of our technology and are now supported with both peer-reviewed clinical data and third-party economic data, proving the value of what we have built. We are eager to continue working on our new commercialization strategy, seeing the impact of our new NOVA-5 software has, and all our initiatives we are undertaking to drive shareholder value and expand PURE EP."
|Over a quarter ago|
Meet BioSig Technologies: Fly exclusive interview with CEO Ken Londoner » 13:0303/3103/31/22
In an exclusive interview…
BioSig CEO sees 'massive amount of pent-up demand' in industry 13:0003/3103/31/22
BioSig shifting from R&D to commercial launch, CEO tells The Fly 13:0003/3103/31/22
BioSig CEO says recent financing gives enough runway to ramp commercial activity 13:0003/3103/31/22
BioSig seeing double-digit increases in elective procedure growth, CEO says 13:0003/3103/31/22